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ABSTRACT OF CAPSTONE 
ESTIMATING THE EFFECTS OF Z-DRUGS ON THE RISK OF 
COGNITIVE IMPAIRMENT 
Background: Dementia and sleep disorders are two significant health problems 
in older adults. Studies suggest that sleep disorders and their treatment might 
associate with the risk of dementia. Z-drugs are one of the most widely used 
prescription hypnosedatives in the United States (US) for insomnia in addition to 
benzodiazepines (BZDs). Studies have shown that BZDs are associated with 
dementia among senior users. Study Aim: The purpose of this study is to 
evaluate the association between Z-drug initiation and cognitive impairment 
among the elderly in the US. Study Design and Data Source: We conducted a 
retrospective cohort study with a new user design using the Uniform Data Set 
(UDS) from the National Alzheimer’s Coordinating Center (NACC) from 2005-
2017. Methods: We performed Inverse Probability of Treatment Weighting 
(IPTW) based on propensity scores generated from data obtained at the study 
baseline and Incidence Density Sampling (IDS) for the non-user control 
selection. Descriptive analysis, repeated measures general linear regression, 
and survival analysis were performed to estimate the crude and adjusted risk of 
Z-drug use and cognitive impairment. Results: The neuropsychological 
outcomes were measured by the Mini-Mental State Examination (MMSE), 
Clinical Dementia Rating (CDR) sum of boxes, and Trail Making Test (TMT) A 
and B. The decreased MMSE, increased CDR summary score, and the 
increased Trail A and Trail B test scores within user groups indicated that 
cognitive function declined over time among the UDS participants regardless of 
the hypnosedative initiation (P<0.05). The significant difference in the change in 
the Trail B test score among Z-drug users compared to non-users suggested that 
Z-drug users had a slower decline in the Trail B test one and two years after 
initiation (P<0.05). Z-drug users also had a worse survival rates than BZD-users 
from one year after initiation in the Kaplan-Meier analysis (P<0.05). 
Conclusions: Most neuropsychological tests showed decline in global cognitive 
and executive function among users and non-users during follow-up. Z-drug 
users had a slower decline in executive function than non-users over time but 
worse survival rates than BZD-users one year after initiation. Future studies with 
a prospective study design may further explore the drug-outcome association 
and the dose-response relationship.    
KEYWORDS: Prescription hypnosedatives, Z-drugs, benzodiazepines, insomnia, 
sleep disorders, dementia, cognitive impairment, executive function, propensity 
score, IPTW, incidence density sampling 
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CHAPTER 1 
INTRODUCTION 
Dementia and sleep disorders are two significant health problems in older 
adults.1 Studies suggest that sleep disorders and their treatment might associate 
with the risk of dementia.1,2 
Dementia and Reversible Dementia 
Dementia Definition, Types, and Prevalence 
Dementia is a clinical syndrome characterized by “a global deterioration of 
mental function in its cognitive, emotional, and cognitive aspects.”3 Dementia 
typically is a cognitive decline with a long period of progression, which often 
includes memory, leading to disability in elderly people.4 Alzheimer’s disease 
(AD) is the most common type of dementia, followed by vascular dementia, 
frontal lobe dementia, and dementia with Lewy bodies.5 Reversible dementias 
are conditions that may be associated with cognitive or behavioral symptoms but 
are not always sufficient to meet the clinical dementia diagnosis.6,7 Furthermore, 
dementias due to medications and other clinical conditions such as normal 
pressure hydrocephalus, thyroid dysfunction, and depression may be reversible.7 
Reversible dementias could be treatable but should not be assumed as fully 
reversible.6 Dementia due to hypnosedative exposure could be considered as 
reversible. Most common types of dementias due to degenerative and vascular 
pathology may not be reversible.7 
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Based on the current epidemiological report, the estimated prevalence of 
dementia is 3.9% in people over 60 years of age, and the estimated incidence of 
dementia is approximately 7.5 per 1000 people per year worldwide.8,9 The 
incidence of dementia ranges from approximately 1 per 100 person-years in 
people aged 60-64 years to >70 per 1000 person-years in people older than 90 
years.9 Based on estimates from the Aging, Demographics, and Memory Study 
(ADAMS), 14% of people age 71 and older in the US have dementia.4 
Additionally, an estimated 5.7 million Americans of all ages are living with AD in 
2018.4 For people who are 65 years and older, one in 10 of them has AD in the 
US.4  
Dementia risk factors & Hypnosedatives and Dementia 
The risk factors for dementia include non-modifiable and modifiable 
factors.4 Non-modifiable factors include age, family history, and the APOE-ԑ4 
genotype. Whereas, modifiable risk factors include cardiovascular comorbidity 
risk factors, education, social and cognitive engagement, traumatic brain injury 
(TBI), diabetes mellitus, cerebrovascular diseases, alcohol consumption, and 
tobacco use.4,10 In addition to these risk factors with well-confirmed evidence, 
there are also modifiable risk factors that may contribute to cognitive impairment 
or dementia without sufficient scientific evidence, such as sleep disorders and 
hypnosedatives.  
Sleep Disorders 
Sleep Disorders Definition, Types, and Significance 
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Clinical sleep disorders typically include insomnia, sleep apnea, 
parasomnias, restless leg syndrome, and narcolepsy.11-13 These disorders occur 
due to a variety of reasons including allergies and respiratory problems, nocturia, 
chronic pain, stress, and anxiety.14 Insomnia, sleep apnea, and parasomnias are 
the most common sleep disorders associated with cognitive impairment.12,15,16  
Specifically, insomnia, one of the most common sleep disorders, refers to 
dissatisfaction with sleep quantity or quality, usually including “difficulty falling 
asleep, frequent nightmare awakenings with difficulty returning to sleep, and/or 
awakening earlier in the morning than desired.”17,18 Insomnia lasts for a month or 
longer, and most of the insomnia cases are secondary - they are the symptom or 
side effect of certain medical conditions, medicines, sleep disorders, and 
substances.19 Insomnia can associate with daytime sleepiness and a lack of 
energy, which may also cause trouble focusing on tasks, paying attention, and 
remembering life events.18 Another common sleep disorder which often 
influences cognitive impairment and the quality of life of older adults is sleep 
apnea. Sleep apnea is defined by “the occurrence of daytime sleepiness, loud 
snoring, witnessed breathing interruptions, or awakenings due to gasping or 
choking in the presence of at least five obstructive respiratory events (apneas, 
hypopneas or respiratory effort related arousals) per hour of sleep.” 20 Besides, 
parasomnia is a disorder characterized by abnormal or unusual behavior of the 
nervous system during sleep, including non-rapid eye movement (NREM)-related 
parasomnias, rapid-eye movement (REM) sleep disorder, and other 
parasomnias.21 REM sleep order is often seen in older adults.22 
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Furthermore, restless leg syndrome (RLS), which is also called Willis-
Ekbom Disease, commonly occurs in the late afternoon or evening hours and is 
most severe at night.23 RLS usually causes unpleasant or uncomfortable 
sensations in the legs and an irresistible urge to move them.23 As a result, people 
with RLS could have difficultly falling asleep or wake up easily.23 Another sleep 
disorder, narcolepsy, affects the brain’s ability to control sleep-wake cycles. 
People with narcolepsy usually feel rested after waking but then feel sleepy 
throughout the day.24  
Clinical sleep disorders do not only induce fatigue, but also have a 
negative impact on health and quality of life.25 Chronic sleep disorders affect 
approximately 30% of adults, and older adults are even more susceptible.26 The 
elderly have a higher prevalence of insomnia due to medical illness, psychiatric 
conditions, side effects from medication, circadian rhythm changes, sleep 
disorders, and psychosocial factors.27 Insomnia in older adults has been 
associated with an increased risk of health problems, including dementia, 
depression, acute myocardial infarction, hypertension, diabetes, and disability.28-
30 However, sleep disorders are often self-reported by individuals to health 
professionals or researchers, and it can be difficult to ascertain sleep 
disturbance. For example, people who have sleep disorders may not report the 
condition because they are under good control with sleeping aids or are unaware 
of the severity of their condition.  
Non-medication treatment of sleep disorders 
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Treatment of sleep disorders involves lifestyle interventions, medical 
devices, and medications.12,13 For lifestyle interventions, maintaining a healthy 
diet and appropriate exercise, sticking to a regular sleeping schedule, limiting 
caffeine intake, decreasing tobacco and alcohol use, and avoiding high 
carbohydrate meals before bedtime help improve the quality of sleep.12,31 
Breathing devices, such as continuous positive airway pressure (CPAP), help 
with sleep apnea by continuously maintaining mild air pressure to keep the 
airways open in people who have breathing issues.32 Medication interventions 
include sleeping pills, melatonin supplements, allergy or cold medication, and 
medications for underlying health issues.12,13 Due to their high prevalence of 
sleep disorders, use of sleep medications is frequent among the elderly 
frequently.27  
Medication treatment of sleep disorders 
Commonly used medications for sleep disorders, especially insomnia, 
sleep apnea, and parasomnia, are prescription hypnosedatives. Use of 
prescription hypnosedative drugs, which are defined as benzodiazepines (BZDs) 
and benzodiazepine-like hypnotics, is currently a focus of research and clinical 
practice. BZDs have been preferred for the treatment for insomnia.12,30 The 
commonly prescribed BZDs include alprazolam, chlordiazepoxide, diazepam, 
and lorazepam.33 The newer non-benzodiazepine hypnosedatives, the so-called 
“Z-drugs”—zopiclone, zolpidem, and zaleplon are also commonly used.12,30 
Studies report that the negative impact of the use of hypnosedatives increases 
with age since older adults are at a higher risk for impaired cognitive and motor 
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function.34 Among the sleep disorders described above, insomnia, sleep apnea, 
and parasomnias are the most common chronic sleep disorders that are 
potentially associated with Z-drug use and cognitive impairment.35,36   
BZD & Z-drug pharmacokinetics and indications 
BZDs and Z-drugs have similar inhibitory effects on the central nervous 
system, with slight differences in indications due to their pharmacological 
mechanisms.33-35 BZDs are used for numerous indications, including anxiety, 
insomnia, muscle relaxation, relief from spasticity caused by central nervous 
system pathology, and epilepsy.37 BZDs enhances the action of the inhibitory 
neurotransmitter- Gamma Aminobutyric Acid (GABA).33 GABA is the most 
common neurotransmitter in the central nervous system.37 GABA is inhibitory: by 
reducing the excitability of neurons, GABA produces a calming effect on the 
brain.37 The hyperpolarization of the postsynaptic membranes in an inhibitory 
synapse make the postsynaptic neuron less excitable.38,39 The GABA-A receptor 
is a ligand-gated chloride-selective ion channel.38 Binding of BZDs to GABA-A 
receptor allosterically enhances binding of GABA.37,38 Therefore, the closed 
chloride channel is open and the cell further hyperpolarizes, making the neuron 
less excitable.37,38 The half-life of BZDs range from one hour to 250 hours in 
general.  
Similarly, Z-drugs also interact with the GABA-A receptor to enhance the 
inhibitory action of GABA.40 The Z-drugs are non-BZD hypnotic agents belonging 
to the imidazopyridine family.6 Z-drugs, which are short-acting GABA agonists, 
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have only been approved for the treatment of insomnia.6,35,41 For example, 
zolpidem acts as an agonist of the BZD-ω1 receptor component of the GABA-A 
receptor complex and is commonly used in patients with insomnia, including 
elderly patients.6 Comparing to BZDs, Z-drugs have a rapid onset, short duration 
of action (the peak time is 2 hours, half time is 1.5-5.5 hours), low tolerance, and 
a low incidence of adverse effects for insomnia treatment.6,7  
Prescription Hypnosedatives and Dementia 
The severity of hypnosedative-induced side effects causes physicians to 
exercise caution.40-42 BZD and other non-selective GABA agonists with hypnotic 
effects similar to those of zolpidem have been shown to disrupt memory in both 
human participants and animal subjects.43 BZD use alone has been associated 
with cognitive impairment. 42,44-46 However, the possibility that Z-drugs, used 
independently of BZDs, increases the risk for dementia has only been indicated 
by limited outcome measures and regular observational study designs.5 
Specifically, studies showed that BZDs are associated with an increased 
risk of dementia in the elderly population, and these risks decreased when BZD 
use was discontinued.47-51 In a population-based case-control study by Billioti de 
Gage et al., BZD use was associated with increased odds of AD (OR=1.51, 95% 
CI: 1.36-1.69) compared to non-users among people aged >66 years old in a 
community in Canada from 2000 to 2009.52 In addition, neuropsychiatric adverse 
events have been reported among Z-drug users, including hallucinations, 
amnesia, and parasomnia.40 Longitudinal studies have also reported increased 
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risk of dementia among older adults with long-term insomnia.44 A study in Taiwan 
by Chen et al. showed that patients with long-term use of hypnotics have more 
than two times of increased risk of dementia, especially those aged 50 to 65 
years.44 The study also showed increased risks of dementia among those with 
long-term insomnia diagnoses after adjusting for relevant chronic 
cerebrovascular conditions (i.e. hypertension, diabetes mellitus, hyperlipidemia, 
and stroke).44  
Meanwhile, adverse effects associated with Z-drugs include nausea, 
headache, dizziness, drowsiness, hallucination and short-term memory loss and 
other psychomotor impairment.5 As a result, the risk of falls and hip fractures is 
also likely.5,41 The residual effect of Z-drugs on next-day cognitive and 
psychomotor behavior has significant impact on lifestyle, safety, and 
occupational considerations, including motor vehicle and machine operation.5,41 
A three-week clinical trial revealed psychomotor retardation in 2% of patients 
receiving zolpidem and in 0% of patients in the placebo group.53 However, there 
are limited clinical data concerning the effects of long-term Z-drug use on 
psychomotor or cognitive functions.5 Thus, the relationship between the use of Z-
drugs and the potential risk of cognitive impairment remains unknown.    
Research gap 
It is unclear whether sleep disorder itself, the hypnosedative use, or both 
increase the risk of cognitive impairment. The association between 
hypnosedative use and cognitive impairment is undetermined based on the 
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current studies. However, prescription hypnosedatives are still commonly applied 
in clinical practice for significant reasons.  
Whether or not sleep disorder alone is a risk factor of cognitive 
impairment, clinicians would still prefer prescribing hypnosedatives to make 
notable improvement in sleep and quality of life for people with sleep disorders. 
For example, studies have demonstrated that the use of BZDs is associated with 
an improvement of sleep duration.54 However, BZDs are less effective in 
reducing sleep latency with prolonged side effects of drowsiness, dizziness, and 
cognitive impairment.55 Alternatively, zaleplon is effective in improving sleep 
latency (time needed to fall asleep) with a rapid onset, short duration of action, 
and low tolerance.27 For example, zaleplon significantly reduced sleep latency by 
22 minutes among the elderly with insomnia in current studies.56,57 If some 
hypnosedatives are more likely to have adverse effects (e.g., cognitive 
impairment) in patients, using alternatives may reduce the risk of undesirable 
effects. Stranks et al. illustrated that the side effect profile associated with Z-
drugs were more benign than those related to the BZDs.58 However, there are 
limited studies to ascertain the long-term adverse effects, including cognitive 
effects, of Z-drugs. Z-drugs have its restrictions in improving sleep disorders too. 
For instance, the improvement of sleep maintenance (duration and number of 
awakenings) and sleep quality with Z-drugs is controversial.27,56 Therefore, it is 
important to examine which treatment method has fewer side effects among 
older adults regarding their comorbidities and other health conditions.30  
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Additionally, although prior studies have shown a potential risk for incident 
dementia among older adults using BZDs and Z-drugs, few of them have 
examined long-term hypnosedative use on cognitive changes.42,44,45,46 Since 
dementia has a long pre-clinical latent period, the current studies may not lasted 
long enough to capture dementia diagnosis.47,48,59 It is possible that people who 
do not develop dementia may still experience cognitive impairment.47,48,59 
Detecting the cognitive impairment and making early medical decisions are also 
essential in dementia prevention and intervention.47,48,59  
Furthermore, the association between hypnosedative use and cognitive 
impairment will be distorted by confounding by indication (e.g., insomnia) if only 
comparing cognitive impairment between hypnosedative users and non-
users.42,44,45 For example, people take hypnosedatives for their insomnia and 
people who do not take hypnosedatives if they do not have insomnia. If insomnia 
is associated with cognitive impairment, users may experience worse cognitive 
impairment than non-users due to insomnia rather than the use of 
hypnosedatives. Also, many studies include prevalent users instead of new users 
in studying cognitive impairment, which might have led to distortion of the results 
because of the mixed effects of different drugs, attrition bias, or recall bias.42,44-46 
For example, if subjects who took Z-drugs for several years recently switched to 
BZDs when they joined in a study, they could be assigned to the BZD treatment 
group. However, these individuals may still be under the influence of Z-drugs. 
This misclassification may decrease the difference on cognitive impairment 
between Z-drug users and BZD-users.  
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Further, comparing the effects of prescriptive hypnosedative users and 
non-users will not capture the difference between BZDs and Z-drugs if both types 
of hypnosedatives are included as one comparison group in the study.45 Most 
research has studied the effect of BZDs on cognitive impairment or BZDs and Z-
drugs together, so research with Z-drug users only is limited. 
Additionally, using prevalent users who may have been on 
hypnosedatives for a long time as a comparison group may introduce healthy 
initiator and healthy adherer bias. The healthy initiator bias comes from the 
selective initiation of preventive treatments among healthy and health-conscious 
patients and the selective channeling of treatments away from frail individuals 
who are at a higher risk of adverse outcomes.9,60,61 The healthy adherer bias 
extends the healthy initiator and frailty bias to patients who adhere to treatment, 
which are more likely to adhere to other healthy behaviors and preventative care 
and are less likely to have experienced changes in frailty.9,60 These two situations 
may distort the drug-outcome association so that treatment looks 
“beneficial”.9,60,61 
Study Aim and Hypothesis 
In the current research, we will conduct a new user design study among a 
retrospective cohort of older adults (≥65 years) from the National Alzheimer’s 
Coordinating Center (NACC).  The new user design will allow us to evaluate the 
effect of prescription hypnosedative use for more than one year on cognitive 
impairment by comparing cognitive change between Z-drug users, BZD-users, 
12 
 
and non-users. We will examine the effects of Z-drugs and BZDs on the risk of 
cognitive impairment and specific cognitive domains (e.g., executive function) 
among long-term users one or two years after drug initiation. We hypothesized 
that Z-drug users will have a higher risk of cognitive impairment than non-users 
and a lower risk of cognitive impairment than BZD-users. 
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CHAPTER 2 
LITERATURE REVIEW 
 Study Population, Inclusion and Exclusion Criteria 
The target population was adults who were 65 years and older in the US 
population who may use prescription hypnosedatives. Participants in the current 
study were drawn from the Uniform Data Set (UDS) database of the National 
Alzheimer’s Coordinating Center (NACC). NACC aggregates mandated standard 
data elements (the UDS) collected by all federally funded Alzheimer’s Disease 
Centers (ADC).62 Most ADC participants in the dataset are evaluated annually 
until their death, after which the majority of participants are evaluated via 
autopsy.62 The NACC started to aggregate UDS data from the ADCs beginning in 
2005, with the ADC participants representing the range of cognitive status: 
normal cognition, mild cognitive impairment (MCI), and dementia.53,63 Trained 
clinicians and clinical personnel collect data from subjects and their-co-
participants (usually a close friend or a family member).53,63 A consensus team or 
a single physician makes the cognitive diagnosis.53,63 Information is collected 
during in-person office visits, home visits, and telephone calls.53,63 In our 
retrospective cohort study, we drew clinical UDS data from the May 2017 data 
freeze. Initial inclusion criteria were participants who were at least 65 years at the 
initial UDS visit; were cognitively normal at the initial visit; had at least one follow-
up UDS visit; and reported no use of Z-drugs or BZDs at the initial visit. This 
yielded an initial sample of 8,136 participants (Figure 1a).  
  METHODS 
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The UDS database contains demographic characteristics, cognitive test 
results, and clinical diagnoses of cognitive status: Normal cognition, Impaired but 
not Mild Cognitive Impairment, Mild Cognitive Impairment, and Dementia.53 The 
diagnostic criteria were uniform across ADCs and were determined based on the 
most frequently used clinical diagnostic criteria, scales for the features of AD, 
and neuropsychological measures from all ADCs.62 Detailed information about 
the UDS study population is available in other literature.62,64-66 
The database also contained self-reported medication use, including the 
exposure of interest: hypnosedative use.53 Specifically, names of medications 
used within two weeks of the UDS visit were recorded by ADCs, so it is possible 
that exposure may not be captured in the database if a participant failed to report 
a medication.53 It is also important to note that ADCs may collect this information 
in a variety of different ways.53 They might have participants bring their 
medications or a list of medications they were taking within two weeks of UDS 
visit to the research assessment, or they may rely on participants’ memory to 
report medications.53 Other important limitations to note regarding the medication 
use data: indication for use, duration, and dose are not recorded in the 
database.53,65 
We excluded participants who had missing data on medication use at the 
initial UDS visit. We did not exclude participants with mental disorders (e.g., 
anxiety, depression, and psychotic disorders) since the majority of mental 
diagnosis information was missing in our dataset. We did not exclude “impaired 
but not MCI” or participants with dementia due to the limited sample size at the 
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study baseline (the UDS visit before hypnosedative initiation). We selected new 
users who did not report hypnosedative use at their initial UDS visit. Then 
participants were assigned to Z-drug user group or BZD-user group based on 
which drug they firstly reported at subsequent UDS visits. We also added a non-
user group as controls for the Z-drug users with the incidence density sampling 
procedure and with a four-fold match to Z-drug users by the year of their UDS 
enrollment.  
Study Design 
Our study was a dynamic cohort study with the study baseline defined as 
the visit immediately prior to that at which new users reported their initiation 
intake of hypnosedatives. We performed a new user design to reduce potential 
biases. In addition to selecting the group of new Z-drug users, we selected a 
group of BZD-users as well as a group of non-users of hypnosedatives. We 
compared Z-drug new users to BZD new users in order to mitigate confounding 
by indication.9 In addition to confounding by indication, the new user design will 
also reduce the healthy initiator bias and healthy adherer bias which may distort 
the drug-outcome association in observational studies.9,60,61  
The New User Design 
The Active Comparator New User Design (ACNU) was developed to avoid 
the biases mentioned above.9 ACNU is regarded as the standard for 
pharmacoepidemiology.9,60 Furthermore, ACNU emulates the intervention part of 
a randomized control trial (RCT).9,60 The ACNU include cohorts of new drug 
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users, followed over time for the health outcomes of interest.9,60 Comparison 
groups are individuals newly prescribed an index drug versus individuals newly 
prescribed a therapeutic alternative or comparator drug.9,60 In our study, the 
index drug was the Z-drug and the comparator was BZDs. To compare with 
results using traditional user versus non-user design, we also added a non-user 
group as a modification of the ACNU.  
Exposure and measures 
Exposure status was determined at the study baseline according to the 
drug intake status: Z-drug initiation, BZDs initiation, and non-initiation. There 
were two comparisons in our study: Z-drug new users versus BZD new users, 
and Z-drug new users versus non-users of either BZDs or Z-drugs. We selected 
new users who did not report hypnosedative use at their initial UDS visit but 
reported initiation of Z-drug or BZD at subsequent UDS visits. We selected non-
users using the incidence density sampling method. 
Incidence Density Sampling for non-users, matching by the NACC enrollment 
year  
To select the study baseline for non-users and to reduce the influence of 
unmeasured confounding factors in our study, we used incidence density 
sampling (IDS), which is often used in nested case-control studies within a 
cohort.9,67 The IDS was to avoid different probability of drug initiation and non-
initiation among users and non-users. In our sampling procedure, we consider Z-
drug users as “cases” and non-users as “controls”. We randomly selected non-
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users from participants who did not report hypnosedative use from the UDS initial 
visit to the year that they were selected as controls (study baseline). We matched 
the non-users to Z-drug new users with a ratio of 4:1 based on their year of UDS 
initial visit. Every time a participant reported Z-drug initiation, four controls were 
randomly selected (Figure 1b). The controls reported no hypnosedative intake 
from the initial UDS visit to the year of users’ initiation. Participants who reported 
Z-drug use later than the time they were selected as controls were still 
considered as non-users on the index date (study baseline) based on the IDS 
method. These late initiation Z-drug users were not on Z-drugs from the UDS 
initial visit to the time they were selected. However, they were not in the risk set 
at the visit after they were selected as controls.67,68 For example, if user A 
initiated Z-drug in 2011 but was randomly selected as a non-user control in 2009, 
user A will be treated as a non-user control for Z-drug users in 2009 and will not 
be selected as a user or non-user after year 2009.  
Covariates and Potential Confounding 
In addition to the exposure of interest, we identified covariates for our 
study based on the literature and substantive knowledge.4,10,42,44-46 Initially 
considered covariates which were associated with both Z-drug use and cognitive 
impairment can be generally classified into five groups: genetic risk factors, 
demographic characteristics, behavioral risk factors, chronic clinical or mental 
conditions, and other medications. Genetic risk factors of Alzheimer’s Disease 
included APOE-ԑ4.4 Demographic characteristics involved age, sex, education, 
and race.4,44 Behavioral risk factors included alcohol abuse, tobacco use, diet 
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and physical activity.42,44-46 We included chronic clinical or mental conditions such 
as BMI, cardiovascular diseases, diabetes, insomnia, sleep apnea, REM 
syndrome, depression, and anxiety in the analysis. We also considered other 
medications such as over the counter hypnosedatives (OTC) and 
antidepressants in the study.4,42,44-46,69  
Directed Acyclic Graph  
We created a directed acyclic graph (DAG) to identify the minimal 
sufficient adjustment sets for estimating the total effect of Z-drugs on cognition.70 
Causal relationships between variables were based on previous 
literature.4,11,42,69,71,72 According to the specified DAG (Figure 2), the suggested 
minimal adjustment set included age, alcohol abuse, cardiovascular conditions, 
depression or anxiety, diabetes, diet or physical activity, education, over-the-
counter hypnosedatives, parasomnia/REM syndrome, race, sex, sleep apnea, 
tobacco use, and unmeasured variables. Since the participants had different 
cognitive status at the study baseline and whether they were normal or not might 
influence the drug-outcome association, we also included the cognitive status at 
the study baseline in the DAG.2,29,44 The potential confounding factors for 
analysis were narrowed down based on data availability (i.e., whether the 
variables are measured in the NACC database). We included age, sex, race, 
antidepressant use, cardiovascular disorders represented by stroke, 
hypertension, and diabetes, alcohol abuse, tobacco use, and cognitive status 
(normal: yes versus no) at the study baseline as potential confounding factors for 
analysis.70 
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Propensity Scores and Weighting 
Covariates were determined at the study baseline, which was defined as-
the visit prior to drug initiation or the index visit for non-users based on the DAG. 
To further reduce the confounding effects in this study, we applied the propensity 
score (PS) method for measured confounders. A PS is the conditional probability 
of treatment or exposure (or corresponding non-treatment or non-exposure) 
given all measured confounders.73,74 Ideally, the probability of treatment is 
unrelated to confounders among participants with the same PS, like in a 
randomized trial but it may not be the case in most observational studies.73,74  
We applied a logistic regression model to estimate the PS score for both 
comparisons: Z-drug users versus BZD-users and Z-drug users versus non-
users. Covariates were selected based on the DAG, including age at study 
baseline, race, antidepressant use, education, alcohol use, stroke, hypertension, 
diabetes, tobacco use, and cognitive status at study baseline (Figure 2). The 
dependent variable for the logistic regression for PS estimation was the 
medication user group. The PS distributions by group are shown in Figures 3a 
and 3b. Treated (Z-drugs) and control (BZD-users or non-users) participants with 
similar PS values had similar covariate distributions and were comparable.61,73-76 
PS matching is a common method to keep baseline characteristics between 
groups in balance.74 However, to avoid the reduced sample size by PS matching 
and to improve the precision, we adopted stabilized inverse probability of 
weighting (SIPTW) for our analysis.73,74,76 
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Unlike matching, weighting does not result in reduction of the original 
sample size.77 The purpose of weighting is to reweight the individuals within the 
original treated and control groups to create a so-called pseudo-population, in 
which there is no longer an association between the confounders and the 
probability of treatment.61,74,75 Two commonly used weighting schemes are IPTW 
and standardized mortality ratio weighting (SMRW).61,74,75 The SMRW uses the 
treated group as the standard population to reflect the proportion in the 
unadjusted treatment population.73,74,78 SMRW is calculated with value “1” in the 
treated and propensity odds in the untreated.78 The IPTW uses the total study 
group as the standard population.73,74,79 To calculate, IPTW is the inverse of the 
estimated PS (1/PS) for treated participants, and the inverse of one minus the 
estimated PS (1/(1-PS)) for control participants.61,74,75 Persons who receive an 
unexpected treatment are weighted up, while patients who receive expected 
treatment are weighted down.73,74 So the pseudo-population is, in theory, 
representative of the participant characteristics in the overall population from 
which the sample was drawn.73,74 Thus, IPTW results in estimates that are 
generalizable to the entire population from which the observed sample was 
taken; the estimated treatment effect is the population average treatment effect 
(ATE).73,74,79 IPTW can be particularly sensitive to the influence of patients who 
receive unexpected treatments.73,74 Precision of estimated effects could be 
improved by stabilizing the weights, by multiplying weights by the marginal 
probability of receiving treatment (in treated) and the marginal probability of not 
receiving treatment (in untreated).73,74  
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Outcome and Measures 
The outcomes of interest in the current study included neuropsychological 
test indicators and clinical indicators. Neuropsychological test indicators are 
changes in global cognitive function and executive function occurring one and 
two years after the index visit. Our outcomes for cognitive function included two 
measures of global cognitive status: the Mini-Mental State Examination 
(MMSE)80 and the Clinical Dementia Rating (CDR) sum of boxes scores.81 The 
MMSE is a widely used test of cognitive function among the elderly, which 
includes tests of orientation, attention, memory, language, and visual-spatial 
skills.80 MMSE ranges from 0-30, with lower scores indicating worse cognitive 
function.65,80 The commonly used single cutoff score of MMSE is 24, lower than 
which indicates abnormal cognition.82 The CDR sum of boxes is a global 
assessment of dementia severity, which is regularly used in clinical and research 
settings.59,81 The CDR sum of boxes scores range from 0.0 to 18.0, with 0.5 as 
the unit increment.59,81 The CDR sum of boxes staging categories include: 0 as 
normal, 0.5-4.0 as questionable cognitive impairment, 4.5-9.0 as mild dementia, 
9.5-15.5 as moderate dementia, and 16.0-18.0 as severe dementia.59,81  
In addition, we also evaluated the association between Z-drug use and 
executive function change one and two years after Z-drug initiation. Executive 
function was measured by the Trail Making Tests (TMT) A (Trail A) and B (Trail 
B).83-85 The TMT is a measure of visual scanning, graphomotor speed, and 
executive function.83 The Trail A focuses more on visual search and motor speed 
skills, while the Trail B focuses more on executive control.84-86 On average, the 
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Trail A test score is 29 seconds, with more than 78 seconds indicating deficiency 
(maximum time allowed = 150 seconds).87-90 The Trail B test score is 75 seconds 
on average with more than 273 seconds as deficiency (maximum time allowed = 
300 seconds).87-90  
For clinical indicators, we evaluated transitions in clinical cognitive status 
from study baseline to two years after drug initiation. Possible cognitive 
transitions included: normal to MCI, normal to dementia, and MCI to dementia. 
The MMSE, CDR sum of boxes, Trail A and Trail B scores were specified as 
continuous variables. The cognitive transition status was categorical.  
Statistical Analysis  
First, we conducted a descriptive analysis of the study population in three 
groups: Z-drug new users, BZD new users, and non-users. Second, we 
conducted regression analysis for the association between treatment methods 
and outcome variables. All regression models for our analysis used the SIPTW 
method.  
Model selection and goodness of fit 
Our primary outcome variables included two types: the continuous 
variables of neuropsychological tests including the MMSE, CDR sum of boxes, 
Trail A and Trail B tests, and the categorical cognitive transition variable as the 
clinical indicator. We applied the repeated measures general linear model for 
outcomes of the MMSE, CDR sum of boxes, and the Trail A and Trail B test 
scores with two repeating time points: one year and two years after drug initiation 
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(two and three years after study baseline for non-users) respectively. We chose 
repeated measures to analyze the association between the continuous variables 
(the MMSE, CDR sum of boxes, Trail A, and Trail B test scores) and the 
exposure of interest due to the fact that the study contained repeated measures 
of the outcomes at two different time points (baseline and one or two years after 
initiation).91 In addition, the repeated linear models could allow us to evaluate the 
cognitive change influenced by both treatment methods and time.  
For continuous outcome variables of neuropsychological tests, we 
compared R-squares between the repeated measure models and non-repeated 
linear regressions. We did linear regressions without repeated measures using 
the change of cognitive test scores as the dependent variables and treatment 
group as the independent variables.  The R-squares of the linear regressions 
were smaller than the repeated general linear regressions (e.g., for MMSE, 
0.0015 <0.0033). So the repeated measures were still the best of fit.   
We used the Cox proportional hazards model to evaluate the effects of Z-
drug use on time to cognitive transition in the two years following drug initiation. 
The cognitive transition was defined as cognitive change from normal to MCI, 
MCI to dementia, or normal to dementia from the study baseline to two years 
after the drug initiation. The cognitive transition in two years after drug initiation 
was: 25 among Z-drug users (11.4%), 35 among BZD-users (9.3%), and 105 
among non-users (13.3%). The survival time of the participants were one year, 
two years, or censored if no cognitive transition at the end of two years after drug 
initiation.  
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The statistical significance level in our study was 0.05. We conducted all 
analyses using SAS 9.4® (SAS Institute, Inc., Cary, NC). 
Sensitivity Analyses 
For the neuropsychological tests measured by continuous variables, we 
performed a repeated general linear regression analysis for trajectories from 
baseline to the end of two years after drug initiation with three repeating time 
points- baseline, one year, and two years after drug initiation. For cognitive 
transitions, we did a sensitivity analysis comparing results from the Cox 
proportional hazards model with the Kaplan-Meier product-limit estimator. We 
conducted the Log-Rank test to estimate the difference of cognitive transitions 
between Z-drug users and their comparison groups. 
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CHAPTER 3 
METHODOLOGY 
 Study Baseline Characteristics 
We selected participants from the NACC UDS dataset (September 2005- 
May 2017) according to the study’s inclusion and exclusion criteria. Based on the 
crude inclusion criteria that we provided for the NACC data request, 8,136 
participants were initially included in the study population, among which 6,134 
reported no hypnosedative use. After sample selection, we included 988 
participants in our analysis. Among these participants, 219 were Z-drug new 
users, 376 were BZD new users, and 788 were non-users randomly selected 
from IDS and matched to Z-drug users based on their NACC enrollment year 
(1:4). In the IDS with matching, 197 out of the 219 Z-drug new users were 
matched to controls at the visits before they first reported the Z-drug initiation.  
Participants’ characteristics at the study baseline (i.e., the visit before drug 
initiation) are shown in Table 1a.  Some characteristics at baseline were similar 
in the comparison of Z-drug users and BZD-users with the following exceptions: 
BZD-users were approximately two years older than Z-drug users (P<0.0001), a 
10% larger proportion of BZD-users were on antidepressants than those of Z-
drug users (P=0.01), an approximately 7% smaller proportion of BZD-users did 
not have hypertension (P=0.01), and a 17% larger proportion of Z-drug users 
were more cognitively normal than BZD-users (P<0.0001). After the IDS and 
matching, most characteristics of Z-drug users and non-users were similar 
  RESULTS 
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without statistically significant difference, except that Z-drug users included more 
individuals who identified as White (P<0.05) and that a 10% larger proportion of 
antidepressant use than non-users (P<0.0001).  
In addition, Table 1b showed arithmetic means of the cognitive test scores 
at study baseline, drug initiation, one year after drug initiation, and two years 
after drug initiation. The MMSE and the CDR sum of boxes were statistically 
different at baseline and at drug initiation between Z-drug new users and the 
BZD-users (P<0.05). All four cognitive test scores were statistically different 
between Z-drug users and the BZD-users at one year after initiation (P<0.05). 
The MMSE was statistically different between Z-drug new users and the BZD-
users two years after initiation (P<0.05). Most test scores did not have 
statistically significant difference between Z-drug users and non-users except for 
the CDR sum of boxes at baseline (P<0.01). 
Z-drug Use and Change of Cognition and Executive Function 
Z-drug new users versus BZD new users  
In this comparison of new users with the repeated measures of general 
linear regression, no statistically significant differences were found between Z-
drug users and BZD-users (Table 2). However, statistically significant changes 
were found within user groups for the CDR sum of boxes and the Trail A test 
score change one year after Z-drug or BZD initiation (P<0.01), and for the CDR 
sum of boxes, and the Trail A and Trail B test scores two years after drug 
initiation (P<0.05). The CDR sum of boxes score was increased by 0.1 in Z-drug 
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users and by 0.2 in BZD-users one year after initiation. The Trail A test score 
was increased by 1.8 seconds in Z-drug users and by 2.7 seconds in BZD-users 
one year after initiation. These changes suggested potential cognitive decline 
and impairment of visual search and motor speed one year after 
initiation.83,84,87,88,92,93 
For changes two years after hypnosedative initiation, the within-subject 
change of all four cognitive test scores was statistically significant (P<0.05). The 
CDR sum of boxes score was increased by 0.3 among both Z-drug users and 
BZD-users, indicating global cognitive impairment based on the CDR criteria.92 
The Trail A test score increased by 3.6 seconds among Z-drug users and by 2.3 
seconds among BZD-users, indicating a slowing down on the Trail A test. The 
Trail B test score increased by 8.6 seconds among Z-drug users and by 7.8 
seconds among BZD-users, indicating a slowing down on the Trail B test. 
To sum up the neuropsychological test results for Z-drug users and BZD-
users: no statistically significant difference was found in the change between 
user groups. Both Z-drug users and BZD-users experienced global cognitive 
impairment and declines in visual search, motor speed, and executive control 
over the two years after drug initiation. 
In addition, there was no statistically significant difference between two 
new user groups on hazards of cognitive transition two years after initiation 
(HR=1.49, 95%CI: 0.88-2.53) although Z-drug users had a 49% increased risk of 
cognitive transition over the two years after drug initiation than BZD-users.  
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Z-drug new users versus Non-users 
In the comparison between Z-drug new users and the non-users, most of 
the outcome variables did not show statistically significant changes except the 
TMT test after Z-drug initiation between users and non-users. The difference of 
the change in the Trail B test score one year and two years after initiation (two 
years and three years after study baseline for non-users) was statistically 
significant between Z-drug users and non-users (P<0.05). Changes in cognitive 
tests over time within Z-drug users or non-users were also found for the CDR 
sum of boxes score (P<0.0001) and the Trail B test score (P<0.01) one year after 
initiation (two years after study baseline for non-users) and for all four test scores 
two years after initiation (three years after study baseline for non-users) (P<0.01).  
The effect sizes for the statistically significant changes one year after 
initiation are as follows. The CDR sum of boxes increased by 0.1 for Z-drug 
users and 0.3 for non-users one year after initiation. The Trail B test score 
increased by 5.1 seconds for Z-drug users and 7.6 seconds for non-users one 
year after initiation. Regarding the between-group comparison, non-users had 
2.5 seconds more decline in the Trail B test than Z-drug users. These changes 
indicated that both Z-drug users and non-users experienced increased global 
cognitive impairment regarding their CDR test and executive function decline 
regarding the Trail B test. However, Z-drug users had a slower decline in 
executive function one year after initiation than non-users. 
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Accordingly, the effect sizes for the statistically significant changes two 
years after initiation are listed below. The MMSE decreased by up to 0.3 points 
for users and 0.4 for non-users two years after initiation. The CDR sum of boxes 
increased by 0.3 for Z-drug users and 0.4 for non-users two years after initiation. 
The Trail A test score increased by 2.4 seconds for Z-drug users and 3.9 
seconds for non-users two years after initiation. The Trail B test score further 
increased by 6.4 for Z-drug users and 12.5 for non-users two years after 
initiation. Accordingly, this difference in the Trail B test means that non-users 
slowed down by 6.1 seconds more than Z-drug users two years after drug 
initiation.83 Overall, the poorer MMSE and CDR scores over time indicated worse 
global cognitive function, and the slower the Trail A and B test scores indicated a 
decline in executive function.80,83,88,92,93 Z-drug users had a slower decline in 
executive function regarding Trail B test than non-users two years after initiation. 
To sum up the change of neuropsychological tests one year and two years 
after initiation - Z-drug users had a slower decline in executive function regarding 
Trail B test over the two years after initiation. Both Z-drug users and non-users 
experienced global cognitive decline and decline in visual search, motor speed, 
and executive control over two years after drug initiation. 
No statistically significant difference was found between Z-drug users and 
non-users on hazards of cognitive transition over two years after initiation 
(HR=0.89, 95%CI: 0.58-1.36) although Z-drug users had a 11% decreased risk of 
cognitive transition over the two years after drug initiation (three years after the 
study baseline) than non-users.  
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Interpretation of the results 
With the SIPTW method for regression analysis, we could apply the 
results and conclusions of our study to the entire study population, which is the 
UDS participants who met the inclusion and exclusion criteria.74,75,79 The smallest 
clinically meaningful change of the MMSE reported by other studies was 1-2 
points a year.94-98 Clinically meaningful change for the CDR sum of boxes is 
0.5.59,92,99 The TMT cutoff points depend on age and education.88-90 Younger age 
and higher education are associated with a better Trail Making performance.88-90 
Studies showed that a change of at least 1.5 times of standard deviations below 
the average in the Trail Making tests would show the cognitive decline.83,100 
Accordingly, the effect size of our results, although some of them were 
statistically significant, may not show clinically meaningful changes. More studies 
are needed in the future to explore how the statistically significant difference of 
the TMT would relate to the clinically meaningful difference.83,100  
Sensitivity analyses 
The repeated measures from baseline to the end of two years after drug 
initiation showed similar results as the repeated measures for one year and two 
years after drug initiation, respectively. The only difference was that the change 
of the Trail A test score was statistically significant between Z-drug users and 
non-users over the two years after drug initiation.  Figure 4 and 5 showed the 
trajectories of the cognitive test score change over the two years. 
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For the comparison of Z-drug users and BZD-users in the MMSE test, 
there was a notably decrease in the MMSE test scores for BZD-users, indicating 
the cognitive decline within each individual over time. The MMSE test scores 
among Z-drug users increased from baseline to one year after initiation and then 
decreased since, indicating an improvement and a decline in cognitive function 
over the two years after initiation. However, none of these changes were 
statistically significant (P=0.15). Meanwhile, the two lines were almost parallel 
with each other, especially from one year to two years after drug initiation, 
indicating no difference in the MMSE change between the two treatment groups 
(P=0.30). 
Similarly, the CDR sum of boxes scores increased over time within each 
individual, indicating more cognitive impairment over time (P<0.0001). However, 
the CDR score decreased from baseline to one year after initiation and increased 
since for Z-drug users, which made an overall change was similar to that for 
BZD-users, suggesting no difference in the change of the CDR sum of boxes test 
between Z-drug users and BZD-users over the two years after initiation.  
Although the Trail A and Trail B test results showed a notable difference 
between Z-drug and BZD-users, the difference was not statistically significant 
between groups (P>0.05). There was a statistically significant change over time 
within each individual (P<0.001) for both the TMT test results, indicating a decline 
in executive control over time.  
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For the comparison of Z-drug users and non-users, although there was 
notable change between user groups, especially from baseline to one year after 
drug initiation for the MMSE and the CDR sum of boxes test scores, the change 
was not statistically significant (P>0.05, Table 3c). The MMSE test scores 
decreased significantly over time, suggesting cognitive decline within-subjects in 
both Z-drug users and non-users respectively. Similarly, the increased the CDR 
sum of boxes scores with a statistical significance over time, suggesting greater 
cognitive impairment over the two years after drug initiation.  
The TMT test scores over the two years showed both between groups and 
within-subjects change (P<0.05). TMT times increased significantly (both the 
Trail A and B) over time, showing a slowing down of executing the tasks in TMT 
tests. However, the difference in the Trail A test score was not statistically 
significant for the analysis comparing baseline with two years after initiation. 
Taking the small effect size of 1.5 seconds into account, we would not consider it 
as a clinically meaningful change as the difference in the Trail B test between Z-
drug users and non-users.83,86,87 In Figure 5, we could see an improvement of the 
Trail A test from baseline to one year after drug initiation and then a decline 
afterwards until the end of two years of initiation for the Z-drug users. The 
increase from baseline to one year may come from a practice effect or a real 
improvement.83-89,93,101 
To sum up, regarding the between-group comparison, both the repeated 
measures comparing baseline with one and two years after initiation and the 
three-time point trajectory analysis showed significant difference in executive 
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function among Z-drug users versus non-users. The executive function declined 
in both Z-drug users and non-users group but faster in the non-user group. This 
suggests that Z-drug users have a slower decline in executive functions than 
non-users among people 65 years and older in the US population.  
Figure 6 showed the survival probability distributions. The Log-Rank test 
showed there was a statistically significant difference between the survival rates 
of Z-drug users and BZD-users (P<0.01), but no statistically significant difference 
between Z-drug users and non-users (P=0.25). The survival rate for both Z-drug 
users and non-users dropped to about 0.20 from one year after initiation, which 
means that a Z-drug user or a non-user has 80% risk of cognitive transition from 
one year after initiation. The survival rate dropped to 0.55 for BZD-users from 
one year after initiation and to less than 0.20 for Z-drug users. It means that a 
BZD-user has 45% risk of cognitive transition and a Z-drug user has 
approximately an 80% risk of cognitive transition from one year after initiation. 
This change of survival rate suggested a reduced risk of cognitive transition from 
normal to MCI, MCI to dementia or normal to dementia for BZD-users in 
comparison to Z-drug users in our study population. The significant difference 
between the survival of Z-drug users and BZD-users from the log-rank test did 
not completely agree with that from the Cox proportional hazards analysis. In the 
comparison of Z-drug users and non-users, both the Kaplan-Meier and the Cox 
analysis showed no statistically significant difference in the risk of cognitive 
transition. In the Cox regression analysis, Z-drug users showed a 21% lower risk 
of cognitive transition over two years after drug initiation without statistically 
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significant difference. However, the Kaplan-Meier showed Z-drug users had a 
slightly higher risk of cognitive transition from one year after drug initiation to two 
years. In the comparison of Z-drug users and BZD-users, both survival analyses 
showed no statistically significant difference either. However, the Cox regression 
suggested a 49% increased risk of cognitive transition among Z-drug users than 
BZD users without significance. The result from the Cox regression agreed with 
the Kaplan-Meier result, which showed about 50% increased risk of cognitive 
transition among Z-drug users than BZD-users. Further analysis with statistically 
significant results is needed to confirm if it was the limited sample size, the 
unbalanced baseline characteristics, or true that Z-drug users had an 
approximately 50% increased risk of cognitive transition than BZD-users over the 
two years after initiation.  
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CHAPTER 4 
RESULTS 
 In our study, all users and non-users had a decline in cognitive function, 
global cognitive impairment, visual scanning, graphomotor speed, and executive 
control. Regarding the between-group comparison, both the repeated measures 
with the two-time point and the three-time point trajectory analysis showed 
significant difference in executive function among Z-drug users versus non-users. 
Specifically, executive function declined in both Z-drug user and non-user groups 
but faster in the non-user group. This suggests that Z-drug users could have a 
slower impairment in executive functions than non-users among people 65 years 
and older in the US population. The Kaplan-Meier analysis showed BZD-users 
had a better survival rate from one year after drug initiation than Z-drug users. 
However, these results could be distorted by confounding by indication. For 
example, for the comparison of Z-drug users and non-users, if Z-drug users had 
better sleep quality, they may have a slower rate of decline in executive 
function.2,10 For the comparison of Z-drug users and BZD-users, it is possible that 
Z-drug users were prescribed with Z-drugs rather than BZDs because their major 
problem was insomnia rather than anxiety or other indications of BZDs.33,35 If 
insomnia is more likely to cause cognitive transition than other indications of 
BZDs, BZD-users would be more likely to have a better survival rate of cognitive 
transition.2,10,18,44,102 
  DISCUSSION AND LIMITATIONS 
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However, our results rejected our hypothesis. Instead, Z-drug users 
showed a slower decline in executive function than non-users but a higher risk of 
cognitive transition than BZD-users in our study.53,63 It is difficult to compare our 
results to most other studies due to the study design and research question. For 
example, our study did not include the dose-response relationship or differentiate 
between Alzheimer’s and non-Alzheimer’s dementia.5 If the reduced number of 
GABA-A receptors in Alzheimer’s dementia mitigate the cognitive impairment 
from hypnosedatives as prior studies have reported, the significant effect for non-
Alzheimer’s cognitive impairment could be attenuated or covered by the 
insignificant Alzheimer’s cognitive impairment.5,103 Meanwhile, not all studies 
have been specifically focused on Z-drugs or have similar measures of cognitive 
outcomes. Most studies about the hypnosedative use and its effects on cognitive 
impairment focused on BZDs or a combination of BZDs and Z-drugs, and 
furthermore, most studies also used dementia diagnosis as the cognitive 
outcome. The evidence of the association of Z-drugs and dementia is restricted 
to a few sub-analyses in BZD studies, suggesting a similar risk of dementia as 
seen with BZDs.44 Cheng et al. found that zolpidem users with a high cumulative 
dose in the first year after initiation had a significantly greater risk of Alzheimer’s 
disease than non-zolpidem users and low cumulative dose users.104 However, 
limitations existed in the study design, data collection, and generalization. 
Limitations 
Limitations of data collection  
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First, in a cohort study, the assignment of exposure and the non-exposure 
group should be based on the exposure status at baseline. However, our study 
used an existing dataset, which was not originally designed for our exposure and 
outcome of interest. Although we defined the exposure group based on the drug 
the participants first reported, differential misclassification could happen during 
follow-up when people switched drugs, stopped using the hypnosedatives which 
they were assigned to in the study, or provided unreliable information by self-
reports. For example, 141 Z-drug users changed drug use status after they 
reported initiation of Z-drugs, among which 126 reported non-use of prescription 
hypnosedatives, 7 reported the use BZDs, and 8 reported the use of both Z-
drugs and BZDs for their first change after Z-drug initiation during the UDS visit. 
Similarly, 192 BZD-users changed drug use status after they initiated BZDs, 
among which 183 reported non-use of prescription hypnosedatives, 3 reported 
the use of Z-drugs, and 6 reported the use of both prescription hypnosedatives 
for their first change after BZD-drug initiation.  
Second, the dataset did not provide precise information for disease 
diagnoses including chronic sleep disorder and potential confounding 
comorbidities. For example, we did not have information on insomnia diagnoses, 
or that of any sleep disorder, or the indication of participants taking the 
hypnosedatives. We assumed that people who took hypnosedatives for at least 
one year would have chronic sleep disorders. Specifically, we used the 
hypnosedative prescription as a surrogate of the insomnia diagnosis. However, 
insomnia is not the only indication of prescription hypnosedatives. BZDs may 
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also be prescribed for other numerous indications including anxiety, muscle 
relaxation, relief from spasticity caused by central nervous system pathology, and 
epilepsy.24,25  
Apart from that, people with chronic sleep disorders may not report all 
hypnosedative usage during follow-ups or may not report the medication history 
accurately due to recall bias, self-report bias, and other information biases. For 
example, the hypnosedative information was self-reported by individuals about 
their drug intake within two weeks before each visit due to the requirements of 
the NACC cognitive tests. However, for our study, there could be information bias 
from self-reports and misclassification from lack of medication information 
beyond two weeks before each visit. 
Third, information regarding initiation dates, termination dates, dose, and 
drug switching were unavailable as well. If cumulative dose plays an important 
role in the outcome-exposure association, our study may distort the association. 
For example, a subject reported Z-drug use at visit two and visit three so we 
assumed the subject was on the Z-drug for the entire year from visit two and visit 
three. However, the person may only take the drug for a few months during the 
year.  
Additionally, there is a potential that Z-drugs may only influence short-term 
memories and cognitive functions as studies showed about the risk of falls and 
fractures. However, the UDS data did not provide information on the memory and 
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cognitive function test results the next few days after participants took 
hypnosedatives. 
Limitations of generalization 
Our study sample is unlikely to be representative of the target population. 
First, our study population had a higher socioeconomic status than the average 
older adults in a general population.105,106 The NACC population had a higher 
proportion of subjects with advanced education than the average older 
population.105,106 Second, the NACC data provided limited information on those 
non-White racial populations.105,106  
Important Methodological Improvement for Future Research 
Despite these limitations, our study provided important methodology 
updates for future research on the association between hypnosedative use and 
cognitive impairment. Specifically, our study included different methods for 
confounding and bias reduction. First, we applied an ACNU design to reduce 
confounding by indication, healthy initiator, and healthy adherer bias. Second, we 
performed IDS to avoid putting the user groups at a disadvantage relative to the 
non-users in terms of time at risk.107 By matching the enrollment year while doing 
the IDS, we reduced the unmeasured confounding factors related to enrollment 
year. Third, we also conducted stabilized IPTW method based on PS to reduce 
the measured potential confounding factors for the drug-outcome association. 
The new user design that we performed allowed us to apply a repeated measure 
regression analysis to investigate the hypnosedative exposure and the cognitive 
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outcome. This analysis not only showed the change before and after drug 
initiation but also trajectories of cognitive change from baseline to one year and 
two years after drug initiation. Our sensitivity analysis gave us a better estimation 
by controlling uncertainties in analytic methods. In the future, if it is possible to 
link claims data to the NACC cohort, we can benefit from both databases. The 
NACC data could provide measures for cognitive tests.53 Additionally, claims 
data could provide additional clinical diagnoses, drug initiation and termination, 
and drug dose.108  
Proposed Improvement of Study Design on the Study of Hypnosedatives and 
Cognitive Impairment 
A better study design with an improved data collection method is needed 
to avoid the above-mentioned limitations of investigating the association between 
prescription hypnosedatives and cognitive impairment. An appropriate study 
design will be more generalizable to the target population, and will make the 
results more applicable to public health and clinical practice. Here are the 
proposed study designs and evaluations of the designs regarding the study 
population, feasibility, potential biases, and ethical issues.  
A proposed study design - An observational study from a medical insurance 
cohort 
Regarding the ethical issues and feasibility of the clinical trials, we could 
also conduct a prospective cohort study with an ACNU design from a medical 
insurance claims data cohort.9,60,61 Similar to our current study, the ACNU design 
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will avoid confounding by indication, healthy initiator, and healthy adherer 
biases.9,60,61 Likewise, the index drug would be Z-drugs and the comparator 
BZDs.9 The Z-drug treatment group could be on any Z-drugs, and the BZD group 
could be on any BZD during the study. The improved ACNU design will allow us 
to reduce misclassification at exposure assignment and with disease diagnoses. 
The proposed study population would be older adults who are at least 65 years, 
have records in the selected database, and are diagnosed with insomnia based 
on ICD codes. 
Possible information that we could obtain also includes prescriptive 
hypnosedative use (initiation and termination dates, dose, and drug names) and 
ICD codes of disease diagnoses such as insomnia, comorbidities, anxiety, 
depression, and other cognitive impairment.6,109 Then, we could conduct a 
retrospective cohort study with the prescriptive hypnosedative use as the 
exposure of interest for older adults with insomnia. The proposed follow-up time 
would be two years from drug initiation. The comparison group will be new Z-
drug users and new BZD-users. Specifically, we will still apply the propensity 
score weighting methods to reduce potential confounding and to emulate a 
clinical trial design.61 
Analytically, this design will be more feasible with fewer ethical issues than 
the clinical trial - such as the ethical issues of intervention assignment and quality 
of life reduction during the washout period. However, more risks of 
misclassification and biases may occur. Misclassification would still occur during 
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follow-up due to the drug switch or missing information of over-the-counter 
hypnosedative use from self-report bias.  
The medical insurance claims data provide better information for 
prescriptive hypnosedative use.110 This will improve the situation that the UDS 
dataset only offered the medication information two weeks before the visits by 
self-report. The claims data will also provide accurate information regarding 
clinical diagnoses of insomnia, other sleep disorders, and comorbidities, so we 
can have better control of the confounding variables.109,110 We could propose to 
explore medical insurance claims from both regular insurance companies and the 
Centers for Medicare and Medicaid Services (CMS).111 However, outcomes of 
interest may be difficult to collect since claims data do not include cognitive tests 
needed for our analysis.108,111 It is also possible that physicians have their 
preference of prescribing certain types of hypnosedatives. This preference may 
lead to channeling bias which may not be avoidable by the study based on the 
claims data. 
To sum up, better designs could be developed but there will be no perfect 
designs for the research. Clinical trials to determine harmful effects are not 
ethical, and all observational data are limited. If the exposure is measured well, 
as in claims data, the outcomes of interest may not be measured as well. 
Appropriate study designs should be selected after evaluating the aims of the 
study, biases, and accuracy of the study results prediction, feasibility, and costs 
of the study, and ethical issues. 
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CHAPTER 5 
IMPLICATIONS FOR PUBLIC HEALTH 
Interestingly, both the cognitive outcome and the hypnosedatives 
exposure in our study are modifiable. In addition, prescription hypnosedative 
exposure is a modifiable factor regarding both patients’ and healthcare providers’ 
“behavior”: how patients take hypnosedatives and how clinicians prescribe 
hypnosedatives. Behavior change, in this sense, is a modifiable factor that has 
the potential to prevent health issues and improve the quality of life in a cost-
efficient way.112 Furthermore, it draws attention to current public health research 
and practice.112-114 One of the aims of our study is to provide evidence of 
suggested prescription behavior change for healthcare providers and policy-
makers and to improve the quality of life of the aging population in the US who 
are on prescription hypnosedatives. Also, the negative findings of the harmful 
effect from Z-drug prescriptions will provide implications to make adjustments for 
clinical and public health practice targeting the senior population through the 
collaboration of multiple-level - patients, healthcare providers, public health 
researchers and practitioners, and policy-makers.   
How our study would help healthcare providers?   
The healthcare system in the US is experiencing a significant transition 
regarding the focus and approaches to improve public health based on the 
change of population structure. According to the US Census Bureau, all baby 
boomers will be 65 years and older by 2030, and there will be 78.0 million people 
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older than age 65 by 2035 compared to 76.7 million who will be under 18 years 
old.115 The fast-growing aging population in the US requires adaptations in 
clinical practice now and in the near future due to the specific changes of 
physiology and heterogeneous health conditions of the elderly.116 However, 
current clinical practices and studies may not be sufficient to reflect the specific 
needs of the elderly.116 This mismatch has led to a lack of evidence-based 
medicine (EBM) in healthcare among the elderly regarding the elderly’s physical 
and psychosocial situation, scientific evidence, and the physicians’ expertise.116 
Fundamentally, clinicians need to acknowledge that the changes of physical, 
mental, and social function of the elderly may lead to their increased vulnerability 
so that clinicians may need to create specific treatment goals and to conduct a 
thorough assessment based on the elderly’s specific situation.116 In addition, 
clinical researches may need to modify study endpoints to target the senior 
population.116  
 For cognitive impairment, a better understanding of the risk of prescription 
hypnosedatives could help with differential diagnoses of dementia for clinicians. 
Clinicians will be able to make prescriptions efficiently specific to the type of 
dementia, which will reduce costs and unnecessary medical treatment for 
patients and their caregivers.4 For example, if Z-drug users showed notably 
cognitive transition one year after drug initiation, clinicians may prescribe 
memantine to slow down the cognitive symptoms.117 However, this may 
associate with over-practice for clinicians if we have insufficient knowledge of 
dementia diagnosis. For instance, memantine may have side effects of body 
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aches, dizziness, constipation, and headache, which are risk factors of falls and 
will decrease the patients’ quality of life.4,117,118 Also, dementia treatment 
medications are also prescribed for long-term use, which may lead to drug 
dependence for the patients.117,118 If the evidence that Z-drug has a higher risk of 
cognitive transition than BZDs is sufficient, clinicians are suggested to prescribe 
BZDs in patients with notable cognitive transition one year after Z-drug initiation. 
If seniors have multiple health conditions, an additional long-term medication 
prescription will also increase the interaction effects between drugs.117,118 For 
example, opioid analgesics may be co-prescribed with hypnosedatives by 
clinicians.119 Studies reported that more than 30% of overdoses involving opioids 
also involve BZDs.119-122 Combining opioids and hypnosedatives can be unsafe 
because both drugs are inhibitory to the central nervous system, which may 
sedate users and suppress breathing.33,35,119-122 The sedative effects of opioid 
and hypnosedatives can be the cause of overdose fatality, in addition to cognitive 
impairment.119,121 As a result, sufficient scientific evidence will allow clinicians 
make a better assessment and treatment plan tailored to the elderly’s specific 
medical needs. 
How our study would help policy-makers?  
For public health policy-makers, cost-effective policies and strategies are 
essential to prevent or postpone cognitive decline in the aging population and to 
improve the quality of life of seniors who are or will be on hypnosedatives. There 
is as of yet no cure for dementia, and dementia care is a financial and physical 
burden for patients, caregivers, and government agencies.4   
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Regarding the changes of the elderly’s physical and psychosocial situation 
and heterogeneous health conditions, it is essential to modify and tailor current 
policies of clinical practice and research according to the specific needs of the 
aging population. First, policy-makers should present a list and order of 
suggested alternative hypnosedatives according to different health conditions so 
that clinicians can help patients to reduce medication interactions through their 
prescriptions.113,123 Second, policy-makers should design the electronic 
prescription system to allow clinicians to justify hypnosedatives types, doses, and 
frequency in the system for patients.113,123 Third, developing a peer comparison 
system through email lists is also essential so that clinicians can compare their 
hypnosedative prescribing rates with others and exchange feedbacks.113,123 
Fourth, adding hypnosedative prescribing to the pay for performance system will 
be helpful to regulate clinicians’ prescription behaviors and to reduce over-
practice more efficiently.124,125 
How our study would help public health researchers and practitioners?  
Furthermore, to increase clinicians’ awareness of the special elements in 
aging-specific practice and the awareness of the seniors and their caregivers on 
improving their quality of life and preventing cognitive impairment, public health 
practitioners could develop an educational program for clinicians, patients, and 
their caregivers about hypnosedative application and risk of cognitive impairment 
among the elderly. For example, this educational program would emphasize the 
importance and benefits of the lifestyle intervention for the patients and their 
caregivers and using medical devices for sleep disorders before clinicians 
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prescribe hypnosedatives with cognitive risks.12,31,114 This educational program 
will also educate clinicians on how to prescribe hypnosedatives with caution and 
justification. Additionally, this program could be developed according to a 
community-based participatory research. For instance, a focus group with 
participants 65 years and older, their caregivers, and clinicians would have a 
panel discussion with public health practitioners and researchers about sleep 
disorders, interventions, and hypnosedative use.126,127 Then the public health 
team will identify priority issues regarding sleep disorders and intervention.126,127 
Then a community-based research protocol of the education program would be 
developed based on the identified priority issues and implemented in 
communities.126 Periodical adjustments and feedback will be made by the public 
health team, and research findings will be disseminated and translated to the 
public and policy-makers.126 
Conclusions 
The decreased MMSE, increased CDR summary score, and the increased 
the Trail A and Trail B test scores within user groups indicated that cognitive 
function declined over time among the UDS participants, whether or not they 
initiated hypnosedatives use. These changes indicated that regardless of 
hypnosedative usage, the cognitive function among the study population will 
decrease over time. The significant change in the Trail B test scores one year 
and two years after Z-drug initiation among Z-drug users compared to non-users 
suggested that Z-drug users had a slower decline in the Trail B test two years 
after drug initiation (three years after baseline for non-users). The Trail B test 
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score usually reflects executive function.84,85,93 Accordingly, we can infer that 
initiating Z-drugs could have a slower decline of executive function compared to 
non-users. However, there was no statistically significant difference between Z-
drug users and BZD-users on the Trail B test. The insignificant results between 
Z-drug users and BZD-users could be due to the limited sample size and biases 
but could also indicate that there’s no difference in cognitive impairment between 
these two types of hypnosedatives. 
So, clinicians may still be suggested to prescribe these drugs for possible 
indications to improve patients’ quality of life due to sleep disorders, anxiety, 
depression, and other related problems.37,65 However, the worse survival rates 
among Z-drug users compared to BZD-users at one year after initiation in the 
Kaplan-Meier analysis suggested that clinicians need to prescribe Z-drugs with 
caution for people with sleep disorders. Future studies with a better sample size 
and study design may explore if BZD-users are more capable in executive 
function than non-users. Studies with dose-response relationships are also 
essential to further investigate the effect of hypnosedatives use on cognitive 
impairment. With a better study design and data collection method, our study will 
be more beneficial to patients, clinicians, and public health policy-makers in the 
prevention of reversible dementia caused by hypnosedatives. 
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APPENDIX TABLES AND FIGURES 
Table 1a. Participants' characteristics at study baseline, NACC, 2005-2017 
 
Characteristics
Z-drug 
users
BZD-users P value Z-drug 
users
Non-users P value
n=219 n=376 n=197 n=788
Age at baseline, y 77.3±7.3 79.4±7.6 <0.001* 77.0±7.3 77.9±7.3 0.12
mean±SD
Education, y 15.8±3.0 15.8±5.4 0.94 15.6±3.0 15.6±4.4 0.85
mean±SD
Sex 0.26 0.55
Male 77 (35.2) 117 (31.1) 67 (34.0) 286 (36.3)
Female 142 (64.8) 259 (68.9) 130 (66.0) 502 (63.7)
Race 0.47
White 195 (89.9) 324 (86.6) 175 (89.7) 654 (83.0) <0.05*
Black 16 (7.4) 40 (10.7) 16 (8.2) 99 (12.6)
Other 6 (2.8) 10 (2.7) 4 (2.1) 35 (4.4)
Missing 2 2 2
Antidepressant use 0.01* <0.001*
No 169 (77.2) 253 (67.3) 152 (77.2) 667 (87.1)
Yes 50 (22.8) 123 (32.7) 45 (22.8) 99 (12.9)
Missing 0 0 22
Hypertension 0.01* 0.94
Absent 89 (41.6) 111 (34.4) 79 (40.7) 335 (43.2)
Recent/active 122 (57.0) 196 (60.7) 113 (58.3) 415 (53.6)
Remote/inactive 3 (1.4) 16 (5.0) 2 (1.0) 25 (3.2)
Missing 5 53 3 13
Diabetes 0.81 0.96
No 198 (90.4) 342 (91.0) 180 (91.4) 699 (91.3)
Yes 21 (9.6) 34 (9.0) 17 (8.6) 67 (8.8)
Missing 22
Tobacco use 0.33 0.62
No 105 (49.1) 146 (45.2) 95 (49.0) 394 (51.0)
Yes 109 (50.9) 177 (54.8) 99 (51.0) 379 (49.0)
Missing 5 53 3 15
Alcohol abuse 0.66 0.94
Absent 205 (95.8) 307 (95.1) 187 (96.4) 747 (96.0)
Recent/active 0 4 (0.5)
Remote/inactive 9 (4.2) 16 (5.0) 7 (3.6) 27 (3.5)
Missing 5 53 3 10
Dementia diagnosis <0.0001* 0.78
Normal 197 (90.0) 276 (73.4) 178 (90.4) 714 (90.6)
Impaired-not-MCI 5 (2.3) 27 (7.2) 4 (2.0) 20 (2.5)
MCI 14 (6.4) 42 (11.2) 13 (6.6) 48 (6.1)
Dementia 3 (1.4) 31 (8.2) 2 (1.0) 6 (0.8)
Z-drug vs. BZD-users Z-drug vs. Non-users, the 
IDS
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Table 1b. Cognitive test means at baseline and during follow up, NACC, 2005-
2017 
 
Characteristics
Z-drug 
users
BZD-users P value Z-drug 
users
Non-users P value
n=219 n=376 n=197 n=788
Baseline
MMSE 28.7±1.7 28.0±3.2 <0.01* 28.7±1.7 28.6±1.8 0.70
mean±SD
CDR sum of boxes 0.3±0.8 1.0±2.8 0.001* 0.3±0.8 0.2±0.5 <0.01*
mean±SD
Trail A 36.6±17.6 39.8±22.0 0.08 36.3±17.6 36.8±17.4 0.73
mean±SD
Trail B 100.9±58.0 112.3±68.9 0.05 98.4±55.5 103.1±59.9 0.32
mean±SD
Initiation
MMSE 28.7±1.9 28.0±3.2 0.01* 28.7±1.9 28.6±1.9 0.69
mean±SD
CDR sum of boxes 0.3±0.8 1.0±2.8 0.001* 0.3±0.8 0.3±0.9 0.77
mean±SD
Trail A 36.6±16.5 39.8±22.0 0.07 36.1±17.0 36.9±17.7 0.60
mean±SD
Trail B 103.1±60.0 112.2±68.9 0.12 99.8±56.9 104.3±59.9 0.36
mean±SD
One year after initiation
MMSE 28.7±1.9 28.2±2.3 0.01* 28.7±1.9 28.5±2.1 0.39
mean±SD
CDR sum of boxes 0.3±0.9 0.6±1.9 <0.05* 0.3±0.9 0.4±1.3 0.40
mean±SD
Trail A 36.0±17.4 41.1±21.5 0.01* 35.8±17.7 37.1±16.8 0.38
mean±SD
Trail B 100.6±58.6 113.4±68.9 <0.05* 99.4±59.0 105.1±62.0 0.30
mean±SD
Two years after initiation
MMSE 28.6±2.0 28.1±2.1 <0.05* 28.5±2.0 28.3±2.3 0.47
mean±SD
CDR sum of boxes 0.5±1.7 0.7±1.7 0.18 0.5±1.8 0.6±1.6 0.66
mean±SD
Trail A 36.7±16.5 40.4±21.0 0.09 36.2±16.8 38.3±19.2 0.25
mean±SD
Trail B 98.3±49.0 111.0±65.4 0.06 96.4±49.7 108.8±66.2 0.05
mean±SD
Z-drug vs. BZD-users Z-drug vs. Non-users, the 
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Table 2a. Z-drug effects on cognitive change, vs. BZD-users, one year after 
initiation 
 
 
Table 2b. Z-drug effects on cognitive change, vs. BZD-users, two years after 
initiation 
 
 
Table 2c. Z-drug effects on cognitive change, vs. BZD-users, one and two-year 
change trajectory 
 
 
 
 
 
 
 
 
 
 
Cognitive tests Between subjects Within subjects
Over one year Time and user interaction
MMSE P=0.55 P=0.76 P=0.22
CDR sum of boxes score P=0.81 P<0.01* P=0.25
Trail A test score P=0.23 P<0.01* P=0.53
Trail B test score P=0.74 P>0.05 P=0.97
Cognitive tests Between subjects Within subjects
Over two years Time and user interaction
MMSE P=0.37 P=0.06 P=0.09
CDR sum of boxes score P=0.57 P<0.0001* P=0.97
Trail A test score P=0.29 P<0.001* P=0.42
Trail B test score P=0.64 P<0.001* P=0.86
Cognitive transition HR=1.49 P=0.14
95%CI: 0.88-2.53
Cognitive tests Between subjects Within subjects
Over two years Time and user interaction
MMSE P=0.30 P=0.15 P=0.18
CDR sum of boxes score P=0.66 P<0.0001* P=0.76
Trail A test score P=0.12 P<0.001* P=0.20
Trail B test score P=0.70 P<0.001* P=0.96
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Table 3a. Z-drug effects on cognitive change, vs. non-users, one year after 
initiation 
 
 
Table 3b. Z-drug effects on cognitive change, vs. non-users, two years after 
initiation 
 
 
Table 3c. Z-drug effects on cognitive change, vs. non-users, one and two-year 
change trajectory 
 
 
 
 
 
 
 
 
 
 
Cognitive tests Between subjects Within subjects
over one year Time and user interaction
MMSE P=0.20 P=0.08 P=0.20
CDR sum of boxes score P=0.70 P<0.0001* P=0.11
Trail A test score P=0.18 P=0.19 P=0.18
Trail B test score P<0.05* P<0.01* P=0.56
Cognitive tests Between subjects Within subjects
over two years Time and user interaction
MMSE P=0.13 P<0.01* P=0.45
CDR sum of boxes score P=0.89 P<0.0001* P=0.47
Trail A test score P=0.07 P<0.001* P=0.35
Trail B test score P<0.01* P<0.001* P=0.24
Cognitive transition HR=0.89 P=0.58
95%CI: 0.58-1.36
Cognitive tests Between subjects Within subjects
over two years Time and user interaction
MMSE P=0.18 P<0.01* P=0.69
CDR sum of boxes score P=0.70 P<0.0001* P=0.47
Trail A test score P=0.03* P<0.0001* P=0.45
Trail B test score P<0.01* P<0.001* P=0.43
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Figure 1a. Study Scheme 
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Figure 1b. Participants selection examples 
 
Notes: User A enrolled in the NACC UDS visit in 2005 and reported Z-drug 
initiation in the UDS visit of 2006. We selected User A as a Z-drug new user 
starting from 2005 (study baseline) and with two follow-ups after Z-drug initiation 
until 2008. Control A1-A4 were randomly selected non-user controls for User A. 
Controls were randomly selected using the incidence density sampling procedure 
based on inclusion and exclusion criteria for non-users: did not report 
hypnosedative use from the UDS enrollment to the time of corresponding Z-drug 
user’s initiation (year of 2006); enrolled into the UDS in the same year as the 
corresponding Z-drug user (year of 2005). Noting that Control A2 altually initiated 
Z-drug use in 2008. However, Control A2 was still selected as a non-user control 
for User A based on the IDS method. The same criteria will be applied to select 
non-user controls for Z-drug users enrolled in the UDS and started initiation in 
other years (shown as User B and controls).     
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Figure 2. DAG for the association between Z-drug and cognitive impairment 
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Figure 3a. Propensity score distributions by treatment group, Z-drug users vs. 
BZD-users 
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Figure 3b. Propensity score distributions by treatment group, Z-drug users vs. 
non-users, IDS 
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Figure 4. Repeated measures of cognitive test at baseline, one year, and two 
years after initiation, Z-drug users vs. BZD-users 
a. MMSE 
 
 
b. CDR sum of boxes 
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c. Trail Making Test-Trail A 
 
d. Trail Making Test-Trail B 
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Figure 5. Repeated measures of cognitive test at baseline, one year, and two 
years after initiation, Z-drug users vs. Non-users 
a. MMSE 
 
b. CDR sum of boxes 
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c. Trail Making Test-Trail A 
 
d. Trail Making Test-Trail B 
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Figure 6a. Kaplan-Meier Analysis Z-drug users vs. BZD-users 
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Figure 6b. Kaplan-Meier Analysis Z-drug users vs. Non-users 
 
 
 
 
 
 
 
 
 
 
 
